Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.47 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 4/20 | 0.45 |
| ▸ | MMP9 | P14780 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15118465 | 0.91 | EGLN1 (0.50) | EGLN1VEGFAMMP2MMP9DRD2 | |
| SCHEMBL12264162 | 0.86 | DRD2 (0.45) | DRD2DRD3ADRA1BADRA1DADRA1A | |
| SCHEMBL12264182 | 0.81 | CNR2 (0.43) | DRD2DRD3CNR2CNR1PKM | |
| SCHEMBL12264174 | 0.77 | CNR2 (0.50) | CNR2CNR1MEN1KMT2A | |
| SCHEMBL13617003 | 0.75 | MMP2 (0.46) | EGLN1VEGFAMMP2MMP9 | |
| SCHEMBL11983509 | 0.75 | DRD2 (0.49) | DRD2DRD3ADRA1B | |
| SCHEMBL24597279 | 0.74 | PKM (0.45) | EGLN1VEGFAMMP2MMP9DRD2 | |
| SCHEMBL9453861 | 0.74 | EGLN1 (0.53) | EGLN1VEGFAMMP2MMP9CNR2 | |
| SCHEMBL13475441 | 0.72 | KDM1A (0.45) | EGLN1VEGFAMMP2MMP9MEN1 | |
| SCHEMBL20224877 | 0.72 | DRD2 (0.66) | EGLN1VEGFAMMP2DRD2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | EGLN1 602/4885VEGFA 2578/4885MMP2 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.